Key result
A combination of rivaroxaban and clopidogrel resulted in partial regression of a recurrent sessile thrombus on the posterior wall of a gigantic left atrium after mitral valve surgery.
Why the study?
Does a combination of rivaroxaban and clopidogrel improve thrombus regression in a patient with a gigantic left atrium and recurrent thrombus despite effective vitamin K antagonist therapy?
Population
A 73-year-old male with recurrent sessile thrombus in a gigantic left atrium
Design
Case report
Authors
Loading...
May offer an alternative for recurrent LA thrombus after VKA failure in giant LA; hypothesis-generating and requires prospective validation.
Case Report (n=1)
No
Does a combination of rivaroxaban and clopidogrel improve thrombus regression in a patient with a gigantic left atrium and recurrent thrombus despite effective vitamin K antagonist therapy?
Off-label use of rivaroxaban combined with clopidogrel successfully reduced a recurrent left atrial thrombus in a patient with a gigantic left atrium and biological mitral valve after VKA failure.
Masárová et al. (2020) conducted a case report in Recurrent left atrial thrombus with gigantic left atrium and atrial fibrillation (n=1). Rivaroxaban and clopidogrel vs. Vitamin K antagonists (previous therapy) was evaluated on Thrombus size reduction. A combination of rivaroxaban and clopidogrel resulted in partial regression of a recurrent sessile thrombus on the posterior wall of a gigantic left atrium after mitral valve surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: